

FORM 51-102F3 - MATERIAL CHANGE REPORT

1. NAME AND ADDRESS OF COMPANY

Telo Genomics Corp.
MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, Ontario M5G 1L7

2. DATE OF MATERIAL CHANGE

December 12, 2022

3. NEWS RELEASE

News releases dated December 12, 2022 was disseminated through the facilities of Newsfile Corp.

4. SUMMARY OF MATERIAL CHANGE

Telo Genomics Corp. appoints Kris Weinberg as Chief Executive Officer

5. FULL DESCRIPTION OF MATERIAL CHANGE

Telo Genomics Corp. (TSX-V: TELO) (OTCQB: TDSGF) (the “**Company**”) announced the appointment of Kris Weinberg as Chief Executive Officer (“**CEO**”), effective December 12, 2022. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President & Chief Technology Officer.

Mr. Weinberg is an accomplished industry veteran and commercial leader with deep, hands-on experience in the field of high value molecular testing, with a focus on the commercialization of innovative oncology technologies. Mr. Weinberg most recently led the commercial activities at Theralink Technologies, where he successfully launched the Theralink Assay for Breast Cancer to physicians and payors nationally in the US. Kris previously held commercial leadership roles at Natera, Guardant Health, Biodesix and Genomic Health; where he was successful in launching innovative cancer tests across multiple platforms.

In connection with Mr. Weinberg's appointment as CEO, the Company has granted 1,000,000 stock options (the “**Options**”) with a term of 5 years and an exercise price of \$0.35 pursuant to the Company's 2022 stock option plan. The Options will vest 25% on the date of grant, with an additional 25% vesting on each anniversary of the date of grant thereafter over a period of 48 months until fully vested. The options expire on December 12, 2027.

In addition, TELO has recently completed the clinical validation of two tests that have been developed to address important unmet clinical needs in the management of multiple myeloma (“**MM**”). TELO's lead product is designed to identify high-risk smoldering multiple myeloma (“**SMM**”) patients who are likely to benefit from earlier treatment intervention. Of greater importance, the test identifies the larger subset of low-risk SMM patients who have a more stable form of the disease, do not require immediate treatment, and can be regularly monitored using TELO's assay. The Company's second MM assay predicts treatment resistance in newly

diagnosed MM patients. Identifying these patients allows physicians to modify their treatment regimens in a timely manner. The test facilitates regular monitoring and, consequently, enables real time treatment modification, as indicated.

6. **RELIANCE ON SUBSECTION 7.1(2) OF NATIONAL INSTRUMENT 51-102**

Not applicable.

7. **OMITTED INFORMATION**

Not applicable.

8. **EXECUTIVE OFFICER**

Christopher Ross, CFO
416-673-8487
info@telodx.com

9. **DATE OF REPORT**

December 13, 2022